Citius Oncology(CTOR.US)

Last Updated 19:00:00 ET
longbridge loading

Citius Oncology | 8-K: FY2026 Q2 Revenue: USD 1.667 M

Earnings Watch·
US
CTOR
+2.07%
Earnings Watch·
US
CTOR
+2.07%

16:30 ETCitius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update

prnewswire·
US
CTXR
+14.64%
US
PBE
+0.67%
US
BBH
+0.85%
prnewswire·
US
CTXR
+14.64%
US
PBE
+0.67%
US
BBH
+0.85%

Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update | CTOR Stock News

StockTitan·
US
CTOR
+2.07%
StockTitan·
US
CTOR
+2.07%

Citius Pharmaceuticals Amends Promissory Note to Enhance Flexibility

Tip Ranks·
US
CTXR
+14.64%
US
CTOR
+2.07%
US
LABU
+3.48%
Tip Ranks·
US
CTXR
+14.64%
US
CTOR
+2.07%
US
LABU
+3.48%

Citius raises $36.5m for Lymphir commercialisation

Pharmaceutical Technology·
US
CTXR
+14.64%
Pharmaceutical Technology·
US
CTXR
+14.64%

Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® Commercialization | CTOR Stock News

StockTitan·
US
CTOR
+2.07%
US
IHE
+1.20%
US
IBB
+0.93%
StockTitan·
US
CTOR
+2.07%
US
IHE
+1.20%
US
IBB
+0.93%
© 2026 Longbridge｜Disclaimer